On Thursday, TD (TSX:TD) Cowen updated its outlook on United Therapeutics Corp . (NASDAQ: NASDAQ:UTHR), raising the price target to $350 from the previous $270, while reiterating a Buy rating on the stock. The increase follows United Therapeutics' announcement regarding its Phase III TETON 2 study of Tyvaso in patients with Idiopathic Pulmonary Fibrosis (IPF), which has now reached full enrollment. Topline data from this study is anticipated in the second half of 2025.
The ongoing enrollment for the TETON 1 and TETON PPF studies was also acknowledged as a positive sign of the company's continued research efforts. TD Cowen's decision to lift the price target is based on feedback from key opinion leaders (KOLs) on the potential of Tyvaso for treating IPF. This feedback led to the inclusion of risk-adjusted peak U.S. sales for Tyvaso in the firm's financial model.
The analyst from TD Cowen expressed confidence in the future performance of United Therapeutics, stating that the updated net present value (NPV)-based price target reflects the company's prospects. The maintained Buy rating indicates a positive outlook on the stock's potential for growth.
Investors and market watchers are now looking forward to the release of the TETON 2 study's topline data, which could provide further insights into the efficacy of Tyvaso in IPF treatment and potentially impact United Therapeutics' market position.
In other recent news, United Therapeutics Corporation reported record revenues of $678 million in a recent quarter, marking a 34% increase year-over-year. This growth was primarily driven by the performance of its drug Tyvaso, which saw revenues surge to $373 million, a 56% increase from the previous year. The company also announced the election of Jan Malcolm, former Minnesota Commissioner of Health, to its Board of Directors.
In analyst news, Morgan Stanley (NYSE:MS) downgraded United Therapeutics from Overweight to Equalweight, despite raising the price target to $321 from the previous $310. On the other hand, Oppenheimer maintained its Outperform rating on United Therapeutics shares and increased the target price to $400 from $375. Meanwhile, BofA Securities revised its price target for the company to $262 from the previous $270, maintaining an Underperform rating.
Additional developments include United Therapeutics' progress in clinical trials and organ manufacturing initiatives, specifically in xenotransplantation. The company has also initiated a $1 billion accelerated share repurchase program, expected to conclude by the end of Q3 2024.
InvestingPro Insights
As TD Cowen raises the price target for United Therapeutics Corp. (NASDAQ: UTHR), it's essential to consider the company's current financial metrics and market performance. United Therapeutics boasts a robust market capitalization of $14.61 billion, along with an attractive P/E ratio of 14.73, which is slightly adjusted to 14.18 when considering the last twelve months as of Q1 2024. The company's financial health is further underscored by its impressive revenue growth of 26.09% over the last twelve months, as of Q1 2024.
Two InvestingPro Tips that are particularly relevant to the article are United Therapeutics' aggressive share buyback strategy and its strong cash position, holding more cash than debt on its balance sheet. These strategic moves are indicative of management's confidence in the company's value and financial stability. Additionally, the company's gross profit margins stand at a remarkable 88.87%, reflecting efficient operations and a potentially favorable outlook for investors.
For readers interested in a deeper dive into United Therapeutics' prospects, there are more InvestingPro Tips available, including insights on the stock's low price volatility and its ability to cover interest payments comfortably. For those considering an investment, using the coupon code PRONEWS24 can provide up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, offering access to these valuable insights and more. Currently, there are 17 additional InvestingPro Tips available for United Therapeutics, which can help investors make well-informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.